AR046769A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR046769A1
AR046769A1 ARP040104804A ARP040104804A AR046769A1 AR 046769 A1 AR046769 A1 AR 046769A1 AR P040104804 A ARP040104804 A AR P040104804A AR P040104804 A ARP040104804 A AR P040104804A AR 046769 A1 AR046769 A1 AR 046769A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
pharmaceutical
cyclodextrin
minus
acceptable
Prior art date
Application number
ARP040104804A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR046769A1 publication Critical patent/AR046769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Composiciones farmacéuticas que comprenden antagonistas de neuroquinina NK1. Reivindicación 1: Una composición farmacéutica que comprende un compuesto de fórmula (1) o una sal del mismo aceptable para uso farmacéutico mezclada con un derivado polianiónico de b-ciclodextrina con aproximadamente uno a aproximadamente siete grupos sulfonato de sodio separados de la cavidad lipofílica por al menos un grupo espaciador de éter butílico.
ARP040104804A 2003-12-22 2004-12-20 Composiciones farmaceuticas AR046769A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53173503P 2003-12-22 2003-12-22

Publications (1)

Publication Number Publication Date
AR046769A1 true AR046769A1 (es) 2005-12-21

Family

ID=34738689

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104804A AR046769A1 (es) 2003-12-22 2004-12-20 Composiciones farmaceuticas

Country Status (16)

Country Link
US (1) US20050153999A1 (es)
EP (1) EP1706116A1 (es)
JP (1) JP2007515425A (es)
KR (1) KR20060113737A (es)
CN (1) CN1897942A (es)
AR (1) AR046769A1 (es)
AU (1) AU2004308935A1 (es)
BR (1) BRPI0417950A (es)
CA (1) CA2550432A1 (es)
MX (1) MXPA06007210A (es)
NO (1) NO20063393L (es)
PE (1) PE20051049A1 (es)
PL (1) PL380482A1 (es)
TW (1) TW200531686A (es)
WO (1) WO2005063243A1 (es)
ZA (1) ZA200605080B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114922A2 (en) * 2006-04-05 2007-10-11 Schering Corporation Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
EP2004148B1 (en) * 2006-04-05 2015-07-15 OPKO Health, Inc. Pharmaceutical formulations comprising salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1 ,7-diazaspiro[4.5]decan-2-one and their medical use
ES2584838T3 (es) 2006-04-05 2016-09-29 Opko Health, Inc Sal clorhidrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decán-2-ona y procedimiento de preparación de la misma
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
CA2743584A1 (en) * 2008-11-23 2010-05-27 Pfizer Inc. Lactams as beta secretase inhibitors
AU2014271269B2 (en) * 2009-08-14 2016-11-03 Opko Health, Inc. Intravenous formulations of neurokinin-1 antagonists
CN105503870A (zh) * 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
CN112472814A (zh) * 2012-01-23 2021-03-12 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
NL2018041B1 (en) * 2016-12-22 2018-06-28 Land Life Company B V Process to prepare a biodegradable pulp product
CA3140046A1 (en) * 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Ketamine formulation for subcutaneous injection
CN113905735B (zh) * 2019-06-28 2024-03-15 福建盛迪医药有限公司 神经激肽-1拮抗剂
BR112022018876A2 (pt) 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US20240016822A1 (en) * 2020-12-25 2024-01-18 Shanghai Shengdi Pharmaceutical Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791346B3 (fr) * 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1

Also Published As

Publication number Publication date
US20050153999A1 (en) 2005-07-14
MXPA06007210A (es) 2006-08-18
WO2005063243A1 (en) 2005-07-14
EP1706116A1 (en) 2006-10-04
PE20051049A1 (es) 2006-01-03
CN1897942A (zh) 2007-01-17
TW200531686A (en) 2005-10-01
KR20060113737A (ko) 2006-11-02
PL380482A1 (pl) 2007-02-05
JP2007515425A (ja) 2007-06-14
ZA200605080B (en) 2008-06-25
AU2004308935A1 (en) 2005-07-14
BRPI0417950A (pt) 2007-04-17
NO20063393L (no) 2006-07-21
CA2550432A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
AR046769A1 (es) Composiciones farmaceuticas
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
CY1108573T1 (el) Ανταγωνιστες νρυυ5
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR061134A1 (es) Derivados de tioxantina
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
EA200300453A1 (ru) Производные 3-ароилиндола и их применение в качестве агонистов рецепторов cb2
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
UY26780A1 (es) Cicloalquil avb3 antagonistas
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
EA200400140A1 (ru) Пероральные противодиабетические агенты
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
PA8579901A1 (es) Bifenilcarboxamidas sustituidas con n-aril piperidina
PA8605101A1 (es) 4-(aminometil)-piperidin benzamidas como antagonista de 5ht4
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal